CN Patent

CN106924268A — 用25‑羟基‑维生素d3治疗与嗜酸性粒细胞趋化因子增高有关的病症

Assigned to DSM IP Assets BV · Expires 2017-07-07 · 9y expired

What this patent protects

本发明涉及用25‑羟基‑维生素D3治疗(麦角钙化固醇(calcifediol))与嗜酸性粒细胞趋化因子增高有关的病症。任选地，维生素D3可以与25‑羟基维生素D3一起使用。

USPTO Abstract

本发明涉及用25‑羟基‑维生素D3治疗(麦角钙化固醇(calcifediol))与嗜酸性粒细胞趋化因子增高有关的病症。任选地，维生素D3可以与25‑羟基维生素D3一起使用。

Drugs covered by this patent

Patent Metadata

Patent number
CN106924268A
Jurisdiction
CN
Classification
—
Expires
2017-07-07
Drug substance claim
No
Drug product claim
No
Assignee
DSM IP Assets BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.